Jefferies Group LLC reissued their hold rating on shares of C.R. Bard, Inc. (NYSE:BCR) in a research report sent to investors on Thursday morning. Jefferies Group LLC currently has a $317.00 price target on the medical instruments supplier’s stock.
Several other research firms have also recently weighed in on BCR. Zacks Investment Research upgraded shares of C.R. Bard from a hold rating to a buy rating and set a $360.00 price target for the company in a report on Monday, July 31st. BidaskClub cut shares of C.R. Bard from a hold rating to a sell rating in a report on Saturday, August 5th. Finally, BMO Capital Markets reiterated a hold rating and issued a $317.00 price target on shares of C.R. Bard in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. C.R. Bard presently has a consensus rating of Hold and a consensus target price of $285.67.
Shares of C.R. Bard (NYSE:BCR) traded down 0.29% during midday trading on Thursday, hitting $319.57. 386,659 shares of the company’s stock were exchanged. The company has a 50-day moving average of $320.21 and a 200-day moving average of $296.89. C.R. Bard has a 52 week low of $203.63 and a 52 week high of $324.58. The firm has a market cap of $23.22 billion, a price-to-earnings ratio of 41.95 and a beta of 0.60.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.54 earnings per share. Equities research analysts expect that C.R. Bard will post $11.84 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “C.R. Bard, Inc. (BCR) Given “Hold” Rating at Jefferies Group LLC” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/c-r-bard-inc-bcr-given-hold-rating-at-jefferies-group-llc.html.
In related news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares in the company, valued at $10,022,464.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares during the last quarter. Parallel Advisors LLC lifted its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in C.R. Bard in the first quarter valued at $148,000. SRS Capital Advisors Inc. lifted its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 4 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new stake in C.R. Bard in the second quarter valued at $192,000. Hedge funds and other institutional investors own 79.34% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.